Literature DB >> 18587575

K313dup is a recurrent CEBPA mutation in de novo acute myeloid leukemia (AML).

Maria J Carnicer1, Adriana Lasa, Marcus Buschbeck, Elena Serrano, Maite Carricondo, Salut Brunet, Anna Aventin, Jorge Sierra, Luciano Di Croce, Josep F Nomdedeu.   

Abstract

The CEBPA gene codes for a transcription factor that has a pivotal role in controlling proliferation and differentiation of myeloid progenitors. Acquired CEBPA mutations have been found in acute myeloid leukemias (AML) with a good prognosis, and most of these patients have a normal karyotype. In this paper, we report four cases that displayed the same K313dup in the CEBPA gene. All four had an AML-M1 with CD7 positivity and T-cell receptor gamma chain (TCR-gamma) rearrangement. This mutation could represent nearly 10% of all CEBPA mutations described to date. K313dup disappeared in samples from patients in complete remission. In transfected cells, the K313dup mutant had reduced protein stability with respect to the wild-type protein. K313dup seems to be selected in leukemic cells, and its frequency in other AML series could be determined using the screening method reported in this paper.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18587575     DOI: 10.1007/s00277-008-0528-2

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  1 in total

1.  The presence of C/EBPα and its degradation are both required for TRIB2-mediated leukaemia.

Authors:  C O'Connor; F Lohan; J Campos; E Ohlsson; M Salomè; C Forde; R Artschwager; R M Liskamp; M R Cahill; P A Kiely; B Porse; K Keeshan
Journal:  Oncogene       Date:  2016-03-21       Impact factor: 9.867

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.